No.

Judul Protokol

Status

1

ML41262
A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine

Aktif (Merekrut)

2

PFIZER A7471067
Real-world utilization and outcomes with “study drug” first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review

Aktif (Merekrut)

3

BTM ASEAN
Bone turnover markers reference database in five
South East Asia Countries

Aktif (Merekrut)

4

MK7684A-002
A Phase 2, Multi-Center, Randomised study to compare the efficacy and safety of MK-7684-A or MK-7684-A Plus Docetaxel versus Docetaxel Monotherapy in the treatment of particpants with Metastatic NSCLC with progressive disease after treatment with a Platinum Doublet Chemo or Immunotherapy

Aktif (Merekrut)

5

MO42541- IMBRAVE251
A Phase III, Open-Label, Randomised Study of ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB Alone in Hepatocellular carcinoma previously treated with atezolizumab and bevacizumab

Aktif (Merekrut)

6

MARIPOSA2
A phase 3, Open-Label, Randomised Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Advanced or Metastatic NSCLC After Osimertinib Failure

Aktif (Merekrut)

7

InCyte Podium (INCMGA0012-304)
A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304)                

Aktif (Merekrut)

8

MARIPOSA
A Randomized Study of JNJ-61186372 and Lazertinib Combination Therapy Versus Single Agent Osimertinib or Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Aktif (Merekrut)

9

ATORG003
A single-arm, open-label, phase 2 study of dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation

Aktif (Merekrut)

10

LAURA
A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive on-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA).

Aktif (Merekrut)

11

Invitrocue PDO for drug screening
Validating the use of patient-derived organoids for predicting drug response to chemotherapy in patients with advanced solid cancers

Aktif (Merekrut)

12

MS200095-0031-INSIGHT 2
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior Osimertinib therapy.

Aktif (Merekrut)

13

CBYL719H12301 – EPIK B3
A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation.

Aktif (Merekrut)

14

ATORG 001
A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study).

Aktif (Merekrut)

15

ATORG004
Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer
(Investigator Initiated Research)

Aktif (Merekrut)

16

CT-P16 3.1
A double-blind, randomized, active-controlled, parallel-Group, Phase 3 study to compare efficacy and safety of CT-P16 and EU-approved Avastin as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer.

Aktif
(Berhenti merekrut)

17

MK7902-007
A Phase III, randomized, double-blind trial of Pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007).

Aktif (Berhenti merekrut)

18

MK3475-394
A Phase III Randomized Double-Blind study of pembrolizumab plus best supportive care as second-line therapy in Asian subjects with previously systematically treated advanced hepatocellular carcinoma

19

MK3475-042
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)

Aktif (Berhenti merekrut)

20

Keynote-590
A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination of cisplatin and 5FU versus placebo in combination with cisplatin and 5FU as first-line treatment in subjects with advanced/metastatic esophageal carcinoma

Selesai

21

EMR200095-006
Phase Ib/II Multicentre, Randomized Open Label Trial to Compare (MSC2156119J) Combined Gefitinib Versus Chemotherapy as Second Line Treatment in Subject with MET (+), Locally Advanced / Metastatic Non-Small Lung Cancer (NSCLC) Harbouring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor

Selesai

22

Tessa FF01:
A Multicentre, Randomised, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr virus-specific Autologous Cytotoxic T Lymphocytes vs Gemcitabine andCarboplatin as first line treatment for Advanced NPC

Selesai

23

Hyperthermia – REMISSION 1C
Hyperthermia in Treating Patients with Unresectable Abdominal, Pelvic tumours and Cutaneous and Peritoneal Metastases

24

TROIKA
A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety, and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer

25

CLEE011A2404
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribocliclib (LEE11) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease

Selesai

26

Studies On Epigenetic Changes In Nasopharyngeal Cancer

Selesai

27

Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care

Selesai

28

Healthcare Performance Measurement And Reporting For Breast Cancer Services In Malaysia

Selesai

(View Abstract)

(View Paper)

29

A Randomized, Phase II, Placebo Controlled Study Of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma

Selesai

30

A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors.

Selesai

31